3 ms·
Yeah putting myself in the shoes of someone with this disease or a loved one with this disease I would be so incredibly angry that we weren't allowed to try som
by snapcaster 8mo ago
Yeah putting myself in the shoes of someone with this disease or a loved one with this disease I would be so incredibly angry that we weren't allowed to try something when the alternative is certain death
- reg_dunlop 8mo agoIt's the prisoner's dilemma. Or more succinctly: Take something and possibly live, or take nothing and certainly die.
- bobbylarrybobby 8mo agoThat's not what the prisoner’s dilemma is.
- petcat 8mo agoYeah this is more like a Pascalian Gamble [1]. If you try nothing, then you are assured to die as God wanted. If you try something, then you might live, but then God hates you. [1] https://en.wikipedia.org/wiki/Pascal%27s_wager https://en.wikipedia.org/wiki/Pascal%27s_wager
- deleted 8mo ago[deleted]
- Liquix 8mo agoIt is like Pascal's Wager but has nothing to do with "what God wanted" or "God hating you"... It's more "if it doesn't work the outcome is the same anyway" (eternal oblivion in Pascal's case, certain death in this case), therefore why not give it a shot in case it does work.
- gverrilla 8mo agoWarning to anyone reading this: Pascal was NOT a self-help writer.
- fiddlerwoaroof 8mo agoI think you could mitigate some of the problems by making the drug company pay for the treatment before approval.
- kulahan 8mo agoThere is a lot of money to be made selling snake oil to the desperate, so we definitely want regulation…
- DennisP 8mo agoSo don't let people sell the drugs at a profit, at early stages.
- Induane 8mo agoDing ding ding this is the way. Sell at cost. Real cost, like cost of making. NOT a cost that includes R&S amortized across the batch.
- vibrio 8mo agoNot even cost plus? Not sure how that works, from the viewpoint of economic incentives.
- ulfw 8mo agoIt's literally free data for efficacy / later sales.
- vibrio 8mo agoSo charging patients/insurance companies at cost to fund the clinical studies?
- DennisP 8mo agoClinical studies today are funded entirely by the pharma companies, keep that. Selling at cost of production would be something extra, for patients who want the drugs but aren't enrolled in an actual study. The company doesn't get solid data it can use for regulatory approval, so making them donate the drugs in that case seems excessive. A downside would be that for drugs that don't cost much to produce, patients might be less willing to enroll in the studies, given the chance of getting a placebo. That could be handled by shutting down the informal access while the study is enrolled, for anyone who's eligible. I'm sure there are other wrinkles that would need to be considered too.